JPRN-jRCT2080225119已完成2 期
A Multicenter Study for the assessment of Positron Emission Tomography (PET) Myocardial Perfusion imaging using NMB58 in Patients with Suspected Ischemic Heart Disease
ihon Medi-Physics Co.,Ltd.0 个研究点目标入组 50 人开始时间: 2020年3月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
Based on the efficacy result, in terms of the diagnostic efficacy of the qualitative diagnosis of 1-day protocol PET myocardial perfusion imaging using NMB58 for similar enrolled subjects in future trials, if SOT could be determined by coronary angiography results, it would be considered reasonable to assume that the expected sensitivity and specificity of PET myocardial perfusion imaging using NMB58 in a blinded manner are both 70%. The safety of twice-daily administration of NMB58 was also confirmed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Provide signed informed consent (IC) prior to undergoing any study procedures.
- •2. Men or women, 20 years of age or older.
- •3. Be willing to continue using an adequate and medically approved method of contraception until safety assessment on Day15 to Day18 (telephone follow-up) is completed from enrollment.
- •4. Scheduled for a clinically-indicated coronary angiogram for assessment of coronary artery disease.
- •5. Be able and willing to communicate effectively with study center personnel and to comply with the instructions of them.
排除标准
- •1. Be pregnant, or may possibly be pregnant, or be lactating.
- •2. With a history of prior myocardial infarction.
- •3. With a history of significant CAD (50% or greater stenosis in 1 or more vessels on coronary angiography).
- •4. With a history of coronary revascularisation, such as percutaneous coronary intervenstion (PCI), thrombolysis or coronary artery bypass graft (CABG) placement.
- •5. Incapable of undergoing either exercise or pharmacological cardiac stress testing. Patients who are incapable of undergoing pharmacological cardiac stress testing shall under any of the following;
- •Unstable angina despite of medication.
- •Second- or third-degree atrioventricular block.
- •Sinus node dysfunction or marked symptomatic sinus bradycardia.
- •Long QT syndrome.
- •Severe hypotension.
- •With suspected or a history of bronchoconstrictive or bronchospastic disease.
- •Known hypersensitivity to adenosine.
- •6. Have a current illness or pathology that, in the opinion of the investigator, would pose a significant safety risk for the patient during cardiac stress testing.
- •7. Unstable cardiovascular condition, including but not limited to:
- •Unstable angina, acute coronary syndrome within 180 days prior to enrollment
- •Transient ischemic attack/stroke within 90 days prior to enrollment
- •Significant congenital heart disease
- •Uncontrolled hypertension (higher than 200mmHg systolic or 110mmHg diastolic, despite of lifestyle modification and use of three or more antihypertensive medications in effective doses including a diuretic)
- •Uncontrolled arrhythmia (unable to take medication due to incomplete or unsatisfactory response to treatment, or side effects associated with QOL reduction)
- •8. Documented history of heart failure and/or cardiomyopathy and/or prior LVEF less than 50%.
- •9. Primary hemodynamically significant uncorrected valvular heart disease, obstructive or regurgitant.
- •10. Scheduled for or planning to undergo any cardiac interventional procedures between enrollment and coronary angiography.
- •11. With screening laboratory findings as follows:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of normal values for each facility
- •Total bilirubin 2.0 mg/dL (34.2umol/L)or greater
- •Serum creatinine 3.0 mg/dL(176.8umol/L) or greater
- •eGFR less than 45mL/min/1.73m2
- •12. Undergoing evaluation for heart transplantation or with a history of heart transplantation.
- •13. Enrolled in another clinical study within the 30 days prior to being enrolled in this study or scheduled to participate in another clinical study during the 7-day follow-up (Day2-Day8) period of this study.
- •14. Previously enrolled in this study or any Flurpiridaz (18F) Injection study.
- •15. Patients who present with any clinically active, serious, life-threatening disease, medical, or psychiatric condition and/or who have a life expectancy lower than 6 months or for whom study participation may compromise their management.
- •16. Whom the investigator judges to be unsuitable for participation in the study for any reason.
研究者
相似试验
已完成
不适用
Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and AdolescentsNon-Hodgkin LymphomaNCT02488369Gustave Roussy, Cancer Campus, Grand Paris230
已完成
不适用
Stool Processing Kit (SPK) Evaluation for Pediatric Tuberculosis (TB)TuberculosisNCT04899076Foundation for Innovative New Diagnostics, Switzerland600
已完成
不适用
A multi centre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair loss.Hair lossNL-OMON26657eids Universitair Medisch Centrum in Leiden260
Unknown
不适用
Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate CancerProstate Cancer RecurrentStage II Prostate CarcinomaStage III Prostate CarcinomaNCT01938339Seoul National University Hospital60
已完成
2 期
Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic SubjectsAtopic AsthmaNCT02758548Novartis Pharmaceuticals193